<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3111">
  <stage>Registered</stage>
  <submitdate>17/03/2011</submitdate>
  <approvaldate>17/03/2011</approvaldate>
  <nctid>NCT01317992</nctid>
  <trial_identification>
    <studytitle>Ibudilast in the Treatment of Medication Overuse Headache</studytitle>
    <scientifictitle>Ibudilast in the Treatment of Medication Overuse Headache: A Double-blind, Randomised, Placebo-controlled Pilot Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IBU-002</secondaryid>
    <secondaryid>U1111-1119-9613</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Medication Overuse Headache</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ibudilast
Treatment: drugs - Placebo

Experimental: Ibudilast - To receive ibudilast 40mg twice daily for 8 weeks.

Placebo Comparator: Placebo - To receive placebo twice daily for 8 weeks.


Treatment: drugs: Ibudilast
Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.

Treatment: drugs: Placebo
Placebo 4 capsules, orally, twice daily for 8 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Headache Index - Headache Index as calculated by the summation of headache duration (hours) X headache intensity (11-point numerical rating scale), over the final two weeks of treatment.</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Medication frequency - Defined as number of days acute headache medication taken over the previous month.</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Headache frequency - Defined as number of days with headache over the previous month</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of headache - Average duration of headache in hours over previous 2 weeks</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intensity of headache - Average intensity of headache assessed by numerical rating scale over previous 2 weeks</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of probable migraine attacks - Defined as number of probable migraine attacks (using International Classification of Headache Disorders, second edition, criteria for diagnosis of migraine/migraine with aura) over previous month</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Headache related impact on quality of life - As assessed via the six-item the Headache Impact Test</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Allodynia symptom checklist score - Assesses presence of cutaneous allodynia during activities of daily living</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Von Frey filament test - To assess sensitivity to static mechanical cutaneous allodynia</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brush allodynia test - To assess sensitivity to dynamic mechanical cutaneous allodynia</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response rate - Response defined as = 30% reduction in headache days/month or headache index from baseline. Expressed as percentage of patients who saw a = 30% reduction in headache index after ibudilast treatment (at week 8) and NNT, number of patients treated to see 1 patient "respond".</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse rate - Expressed as the percentage of patients who were initially classed as responders (at weeks 8) who no longer meet the criteria for responders at 6 months</outcome>
      <timepoint>2, 4, 8, 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Regular use, for at least 3 months, of opioid-containing analgesics on = 10 days/month

          -  Headache present on at least 15 days/month, for at least 2 months

          -  Headache developed or markedly worsened during medication overuse

          -  Primary indication for analgesics is headache disorder</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Unable to provide written informed consent

          -  Age &lt; 18 years at time of screening

          -  Unable to read and write in English

          -  Receiving tramadol regularly

          -  Taking triptans &gt; 4 days/month

          -  Taking opioids for reasons other than headache (e.g. other pain conditions, cough,
             bowel motility)

          -  Severe psychiatric disorders

          -  Other chronic pain conditions likely to interfere with qualitative sensory testing
             (e.g. trigeminal neuralgia, arthritis)

          -  Diabetic neuropathy

          -  Recent or current active infection, determined to be clinically significant by the
             Principal investigator

          -  Known active inflammatory diseases such as rheumatoid arthritis

          -  History of cerebrovascular disorder

          -  Recent history of significant trauma, as determined by the Principal Investigator
             including major surgery within the previous 2 months

          -  Recent history of drug or alcohol abuse

          -  Spinal cord injury

          -  Any clinically significant findings on screening blood sample results

          -  Current malignancy

          -  Known hypersensitivity to ibudilast or excipients in PinatosÂ® formulation

          -  Renal or hepatic impairment, defined as baseline GFR (as calculated by the
             Cockcroft-Gault equation) of &lt; 60 mL/min or LFTs &gt; 3 times the upper limit of normal

          -  For females of childbearing potential:

               -  Pregnancy

               -  Lack of adequate contraception (abstinence, double barrier method, intrauterine
                  device, surgical sterilization (self or partner), hormonal contraceptive methods
                  (oral, injected, or implanted)

               -  Breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2013</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Pain and Anaesthesia Research Clinic, Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Adelaide</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of South Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if ibudilast is effective in reverting patients
      with medication overuse headache suffering chronic daily headache back to their original
      episodic headache pattern.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01317992</trialwebsite>
    <publication>Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008 Nov 25;71(22):1821-8. doi: 10.1212/01.wnl.0000335946.53860.1d. Review.
Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007 Sep;7(9):1145-55. Review.
Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal. 2007 Nov 2;7:98-111. Review.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Rolan, MD FRACP</name>
      <address>The University of Adelaide</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Paul Rolan, MD FRACP</name>
      <address />
      <phone>+61 8 8303 4102</phone>
      <fax />
      <email>paul.rolan@adelaide.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>